drugset / Trial / NCT06014762
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies
Timeline
- Start
- 2024-04-16
- Primary completion
- 2029-03
- Completion
- 2041-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | P-CD19CD20-ALLO1 | Cell therapy | — | Intravenous |
| Background | Rimiducid | Other / unclassified | — | Intravenous |